Erratum: Lovastatin blocks Kv1.3 channel in human T cells: A new mechanism to explain its immunomodulatory properties (Scientific Reports (2016) 5 DOI: 10.1038/srep17381);Lovastatin blocks Kv1.3 channel in human T cells: A new mechanism to explain its immunomodulatory properties

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhao, Ning ^a   Dong, Qian ^a   Qian, Cheng ^a   Li, Sen ^a   Wu, Qiong Feng ^a   Ding, Dan ^a   Li, Jing ^a   Wang, Bin Bin ^a   Guo, Ke Fang ^b   Xie, Jiang Jiao ^a   Cheng, Xiang ^a   Liao, Yu Hua ^a   Du, Yi Mei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MEVINOLIN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; TRANSCRIPTION FACTOR NFAT;

ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; JURKAT CELL LINE; MEMBRANE POTENTIAL; METABOLISM; MUTATION; T LYMPHOCYTE;

CALCIUM; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; INTERLEUKIN-2; JURKAT CELLS; KV1.3 POTASSIUM CHANNEL; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; LOVASTATIN; MEMBRANE POTENTIALS; MUTATION; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; POTASSIUM CHANNEL BLOCKERS; T-LYMPHOCYTES;

EID: 84948672309     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21655     Document Type: Erratum

References (50)

1. Bu D. X., Griffin G., & Lichtman A. H. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 22, 165-170 (2011
2. Chow S. C. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz) 57, 243-251 (2009
3. Zeiser R., et al. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 127, 18-25 (2009
4. Jain M. K., & Ridker P. M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4, 977-987 (2005
5. Pasterkamp G., & van Lammeren G. W. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther 8, 1235-1237 (2010
6. Siu C. W., Lau C. P., & Tse H. F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92, 1343-1345 (2003
7. Khattri S., & Zandman-Goddard G. Statins and autoimmunity. Immunol Res 56, 348-357 (2013
8. Stanislaus R., Gilg A. G., Singh A. K., & Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 333, 167-170 (2002
9. Brumeanu T. D., Goldstein R., & Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin Immunol 119, 1-12 (2006
10. Leung B. P., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170, 1524-1530 (2003
11. Azuma R. W., et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 64, 412-420 (2004
12. Gullu S., Emral R., Bastemir M., Parkes A. B., & Lazarus J. H. In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto?s thyroiditis. Eur J Endocrinol 153, 41-48 (2005
13. Ghittoni R., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. Faseb J 19, 605-607 (2005
14. Dunn S. E., et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203, 401-412 (2006
15. Gegg M. E., et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J Immunol 174, 2327-2335 (2005
16. Beeton C., et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103, 17414-17419 (2006
17. Cahalan M. D., & Chandy K. G. The functional network of ion channels in T lymphocytes. Immunol Rev 231, 59-87 (2009
18. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 7, 690-702 (2007
19. Zhao N., et al. Potent Suppression of Kv1.3 Potassium Channel and IL-2 Secretion by Diphenyl Phosphine Oxide-1 in Human T Cells. Plos One 8, e64629 (2013
20. Fu X. X., et al. 18beta-Glycyrrhetinic acid potently inhibits Kv1.3 potassium channels and T cell activation in human Jurkat T cells. J Ethnopharmacol. 148, 647-654 (2013
21. Price M., Lee S. C., & Deutsch C. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc Natl Acad Sci USA 86, 10171-10175 (1989
22. Leonard R. J., Garcia M. L., Slaughter R. S., & Reuben J. P. Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA 89, 10094-10098 (1992
23. Rangaraju S., Chi V., Pennington M. W., & Chandy K. G. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin Ther Targets 13, 909-924 (2009
24. Fasth A. E., Cao D., van Vollenhoven R., Trollmo C., & Malmstrom V. CD28nullCD4+ T cells-characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol 60, 199-208 (2004
25. Viglietta V., Kent S. C., Orban T., & Hafler D. A. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 109, 895-903 (2002
26. Beeton C., et al. Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98, 13942-13947 (2001
27. Ahn H. S., et al. Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn Schmiedeberts Arch Pharmacol 374, 305-309 (2007
28. Ahn H. S., et al. Calcineurin-independent inhibition of Kv1.3 by FK-506 (tacrolimus): a novel pharmacological property. Am J Phydiol Cell Physiol 2, C1714-C1722 (2007
29. Xie Z., et al. Human alpha-defensins are immune-related Kv1.3 channel inhibitors: new support for their roles in adaptive immunity. Faseb J 29, 4324-4333 (2015
30. Grissmer S., Lewis R. S., & Cahalan M. D. Ca2+ -activated K+ channels in human leukemic T cells. J Gen Physiol 99, 63-84 (1992
31. Zhao N., et al. Acacetin blocks kv1.3 channels and inhibits human T cell activation. Cell Physiol Biochem 34, 1359-1372 (2014
32. Villalonga N., et al. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. Biochem Pharmacol 80, 858-866 (2010
33. Li Z., et al. Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 250, 9-17 (2012
34. Randriamampita C., & Trautmann A. Ca2+ signals and T lymphocytes; New mechanisms and functions in Ca2+ signalling. Biol Cell 96, 69-78 (2004
35. Kazama I., Baba A., & Maruyama Y. HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K+ -channel currents in murine thymocytes. Pharmacol Rep 66, 712-717 (2014
36. Holstein S. A., Knapp H. R., Clamon G. H., Murry D. J., & Hohl R. J. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57, 155-164 (2006
37. Yellen G., Jurman M. E., Abramson T., & MacKinnon R. Mutations affecting internal TEA blockade identify the probable poreforming region of a K+ channel. Science 251, 939-942 (1991
38. Choi J. S., et al. Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J Pharmacol Exp Ther 291, 1-6 (1999
39. Choi J. S., Hahn S. J., Rhie D. J., Jo Y. H., & Kim M. S. Staurosporine directly blocks Kv1.3 channels expressed in Chinese hamster ovary cells. Naunyn Schmiedeberts Arch Pharmacol 359, 256-261 (1999
40. Robe R. J., & Grissmer S. Block of the lymphocyte K+ channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single point mutation. Br J Pharmacol 131, 1275-1284 (2000
41. Schmid S. I., & Grissmer S. Effect of verapamil on the action of methanethiosulfonate reagents on human voltage-gated Kv1.3 channels: implications for the C-type inactivated state. Br J Pharmacol 163, 662-674 (2011
42. Leonard R. J., Garcia M. L., Slaughter R. S., & Reuben J. P. Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA 89, 10094-10098 (1992
43. Cahalan M. D., Wulff H., & Chandy K. G. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 21, 235-252 (2001
44. Lewis R. S., & Cahalan M. D. Potassium and calcium channels in lymphocytes. Annu Rev Immunol 13, 623-653 (1995
45. Cheng S. M., et al. Modulation of human T cells signaling transduction by lovastatin. Int J Cardiol 140, 24-33 (2010
46. Schonbeck U., & Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109, I18-I26 (2004
47. Kwak B. R., Mulhaupt F., & Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2, 332-338 (2003
48. Sarkey J. P., Richards M. P., & Stubbs E. J. Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome. J Neurochem 100, 1265-1277 (2007
49. Ghanshani S., et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 275, 37137-37149 (2000
50. Dong Q., et al. Blocking of the human ether-a-go-go-related gene channel by imatinib mesylate. Biol Pharm Bull 36, 268-275 (2013